866-997-4948(US-Canada Toll Free)

Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Oncology

No. of Pages : 213 Pages


Global Markets Directs, Metastatic Renal Cell Carcinoma Pipeline Review, H1 2015, provides an overview of the Metastatic Renal Cell Carcinomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 4
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Renal Cell Carcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 9
Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 10
Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 11
Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Renal Cell Carcinoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Metastatic Renal Cell Carcinoma - Products under Development by Companies 20
Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 23
Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 24
Acceleron Pharma, Inc. 24
Activartis Biotech GmbH 25
AlphaMab Co., Ltd 26
Amgen Inc. 27
Angiogene Pharmaceuticals Ltd. 28
Argos Therapeutics, Inc. 29
Astellas Pharma Inc. 30
Beta Pharma, Inc. 31
Bionomics Limited 32
Cerulean Pharma, Inc. 33
Conkwest, Inc. 34
Debiopharm International S.A. 35
Eisai Co., Ltd. 36
Eli Lilly and Company 37
Epirus Biopharmaceuticals, Inc. 38
Exelixis, Inc. 39
Genor BioPharma Co., Ltd. 40
Hospira, Inc. 41
immatics biotechnologies GmbH 42
Immune Design Corp. 43
Immunicum AB 44
Inbiopro Solutions Pvt. Ltd. 45
Jiangsu Hengrui Medicine Co., Ltd. 46
Mabion SA 47
NewLink Genetics Corporation 48
Novartis AG 49
Ono Pharmaceutical Co., Ltd. 50
Panacea Biotec Limited 51
Peloton Therapeutics, Inc. 52
Prima BioMed Ltd. 53
Rexahn Pharmaceuticals, Inc. 54
Seattle Genetics, Inc. 55
Syndax Pharmaceuticals, Inc. 56
TVAX Biomedical, Inc. 57
Metastatic Renal Cell Carcinoma - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
AGS-003 - Drug Profile 69
AGS-16C3F - Drug Profile 72
AGS-16M8F - Drug Profile 73
aldesleukin - Drug Profile 74
AV0-113 - Drug Profile 75
bevacizumab biosimilar - Drug Profile 76
bevacizumab biosimilar - Drug Profile 77
bevacizumab biosimilar - Drug Profile 78
bevacizumab biosimilar - Drug Profile 79
bevacizumab biosimilar - Drug Profile 80
bevacizumab biosimilar - Drug Profile 81
bevacizumab biosimilar - Drug Profile 82
bevacizumab biosimilar - Drug Profile 83
BNC-105 - Drug Profile 84
BNC-105P - Drug Profile 85
BPI-3119 - Drug Profile 87
cabozantinib s-malate - Drug Profile 88
CRLX-101 - Drug Profile 91
CST-101 - Drug Profile 93
dalantercept - Drug Profile 95
Debio-0932 - Drug Profile 97
Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 99
entinostat - Drug Profile 100
everolimus - Drug Profile 104
G-305 - Drug Profile 109
Hyperacute For Renal Cancer - Drug Profile 110
IBPM-002BZ - Drug Profile 111
IMA-901 - Drug Profile 112
IMP-321 - Drug Profile 114
Intuvax - Drug Profile 116
lenvatinib - Drug Profile 117
LY-2510924 - Drug Profile 121
Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma - Drug Profile 122
nivolumab (recombinant) - Drug Profile 123
Orellanine - Drug Profile 128
panobinostat - Drug Profile 129
PT-2385 - Drug Profile 135
Recombinant Protein for Oncology - Drug Profile 136
rilotumumab - Drug Profile 137
RX-0201 - Drug Profile 139
SGN-CD70A - Drug Profile 141
SHR-1020 - Drug Profile 142
trebananib - Drug Profile 144
TVI-Kidney-1 - Drug Profile 147
ZD-6126 - Drug Profile 148
Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 149
Metastatic Renal Cell Carcinoma - Dormant Projects 195
Metastatic Renal Cell Carcinoma - Discontinued Products 199
Metastatic Renal Cell Carcinoma - Product Development Milestones 200
Featured News & Press Releases 200

Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210

List of Table


Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2015 27
Metastatic Renal Cell Carcinoma - Pipeline by Activartis Biotech GmbH, H1 2015 28
Metastatic Renal Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H1 2015 29
Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2015 30
Metastatic Renal Cell Carcinoma - Pipeline by Angiogene Pharmaceuticals Ltd., H1 2015 31
Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2015 32
Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2015 33
Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2015 34
Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2015 35
Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2015 36
Metastatic Renal Cell Carcinoma - Pipeline by Conkwest, Inc., H1 2015 37
Metastatic Renal Cell Carcinoma - Pipeline by Debiopharm International S.A., H1 2015 38
Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2015 39
Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2015 40
Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41
Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2015 42
Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2015 43
Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H1 2015 44
Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H1 2015 45
Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2015 46
Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2015 47
Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 48
Metastatic Renal Cell Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 49
Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2015 50
Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2015 51
Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2015 52
Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 53
Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2015 54
Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2015 55
Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2015 56
Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 57
Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2015 58
Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 59
Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2015 60
Assessment by Monotherapy Products, H1 2015 61
Number of Products by Stage and Target, H1 2015 63
Number of Products by Stage and Mechanism of Action, H1 2015 66
Number of Products by Stage and Route of Administration, H1 2015 69
Number of Products by Stage and Molecule Type, H1 2015 71
Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2015 152
Metastatic Renal Cell Carcinoma - Dormant Projects, H1 2015 198
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2015 199
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2015 200
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2015 201
Metastatic Renal Cell Carcinoma - Discontinued Products, H1 2015 202

List of Chart


Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 61
Number of Products by Top 10 Targets, H1 2015 62
Number of Products by Stage and Top 10 Targets, H1 2015 62
Number of Products by Top 10 Mechanism of Actions, H1 2015 65
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 65
Number of Products by Top 10 Routes of Administration, H1 2015 68
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 68
Number of Products by Top 10 Molecule Types, H1 2015 70
Number of Products by Stage and Top 10 Molecule Types, H1 2015 71

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *